NAIR, VSHARMA, ADAS, SSHARMA, SGROVER, NKAUR, J2015-02-242015-02-242013-01NAIR V, SHARMA A, DAS S, SHARMA S, GROVER N, KAUR J. Allogeneic haematopoietic stem cell transplantation: The Army hospital experience. National Medical Journal of India. 2013 Jan-Feb ; 26 (1): 6-11.http://imsear.searo.who.int/handle/123456789/156319Background. We analysed the results of allogeneic haematopoietic stem cell transplantation (HSCT) in various genetic disorders, bone marrow failures and haematological malignancies done from 2002 to 2010 at the Army Hospital, Research and Referral, Delhi. Methods. A total of 119 matched-related allogeneic- HSCTs (allo-HSCTs) were done in 114 patients (men 76, women 38) aged between 2 and 60 years. Peripheral blood stem cells (n=75) and bone marrow (n=43) were used as the source of stem cells. Results. The overall survival was 62.3% (71/114) at a median follow-up of 34 months. Graft versus host disease (GVHD) was seen in 42 (36.8%) patients; grade III/IV acute GVHD in 17 (15%) and chronic GVHD in 24 (21%) patients. There were 4 (3.5%) graft rejections and one nonengraftment. The overall mortality was 37.7% (n=43) and the main causes of death were GVHD (32%), infections (26%), relapse (23%) and regimen-related toxicity (11%). Conclusion. Our results are comparable to published data in most disease conditions. With improvements in GVHD prophylaxis and better supportive care, we need to further reduce our mortality and morbidity.enAdolescentAdultBone Marrow Diseases --therapyChildChild, PreschoolFemaleGenetic Diseases, Inborn --therapyGraft Rejection --etiologyGraft vs Host Disease --etiologyHematologic Neoplasms --therapyHematopoietic Stem Cell Transplantation -adverse effectsHospitals, MilitaryHumansIndiaKaplan-Meier EstimateMaleMiddle AgedSurvival RateTransplantation, HomologousYoung AdultArticle